Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Mucic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.69 |
| ▸ | PDE4A | P27815 | 1/20 | 0.63 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.55 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | THRB | P10828 | 1/20 | 0.38 |
| ▸ | RECQL | P46063 | 1/20 | 0.38 |
| ▸ | OR51E2 | Q9H255 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 2/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.35 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.35 |
| ▸ | F2 | P00734 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Mucic Acid SCHEMBL5312196 | 1.00 | TSHR (0.69) | TSHRPDE4ACYP2C9TP53ALDH1A1 | |
| Mucic Acid SCHEMBL15895451 | 1.00 | TSHR (0.69) | TSHRPDE4ACYP2C9TP53ALDH1A1 | |
| Mucic Acid SCHEMBL5496 | 1.00 | TSHR (0.69) | TSHRPDE4ACYP2C9TP53ALDH1A1 | |
| Mucic Acid SCHEMBL5497 | 1.00 | TSHR (0.69) | TSHRPDE4ACYP2C9TP53ALDH1A1 | |
| Mucic Acid SCHEMBL18871641 | 1.00 | TSHR (0.69) | TSHRPDE4ACYP2C9TP53ALDH1A1 | |
| Mucic Acid SCHEMBL77363 | 1.00 | TSHR (0.69) | TSHRPDE4ACYP2C9TP53ALDH1A1 | |
| Mucic Acid SCHEMBL19695496 | 1.00 | TSHR (0.69) | TSHRPDE4ACYP2C9TP53ALDH1A1 | |
| Mucic Acid SCHEMBL7224759 | 1.00 | TSHR (0.69) | TSHRPDE4ACYP2C9TP53ALDH1A1 | |
| Mucic Acid SCHEMBL17594183 | 1.00 | TSHR (0.69) | TSHRPDE4ACYP2C9TP53ALDH1A1 | |
| Mucic Acid SCHEMBL5901 | 1.00 | TSHR (0.69) | TSHRPDE4ACYP2C9TP53ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250255781-A1 | PROCESSES FOR PREPARATION OF 3-D PRINTED PHARMACEUTICAL PRODUCTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2025-08-14 | — | — | US | claimed |
| US-12296043-B2 | Liquisoft capsules | PATHEON SOFTGELS INC. (US) | 2025-05-13 | — | — | US | claimed |
| EP-4510999-A1 | PROCESSES FOR PREPARATION OF 3-D PRINTED PHARMACEUTICAL PRODUCTS | Bristol-Myers Squibb Company (US) | 2025-02-26 | — | — | EP | claimed |
| CN-119212681-A | Method for preparing 3-D printed pharmaceutical products | 百时美施贵宝公司 | 2024-12-27 | — | — | CN | claimed |
| US-20240165020-A1 | LIQUISOFT CAPSULES | PATHEON SOFTGELS INC (US) | 2024-05-23 | — | — | US | claimed |
| EP-4360653-A2 | LIQUISOFT CAPSULES | Patheon Softgels Inc. (US) | 2024-05-01 | — | — | EP | claimed |
| US-11872307-B2 | Liquisoft capsules | PATHEON SOFTGELS INC. (US) | 2024-01-16 | — | — | US | claimed |
| EP-3682872-B1 | LIQUISOFT CAPSULES | PATHEON SOFTGELS INC (US) | 2024-01-03 | — | — | EP | claimed |
| WO-2023205619-A1 | PROCESSES FOR PREPARATION OF 3-D PRINTED PHARMACEUTICAL PRODUCTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2023-10-26 | — | — | WO | claimed |
| US-20220211616-A1 | LIQUISOFT CAPSULES | PATHEON SOFTGELS INC (US) | 2022-07-07 | — | — | US | claimed |
| US-20250255781-A1 | PROCESSES FOR PREPARATION OF 3-D PRINTED PHARMACEUTICAL PRODUCTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2025-08-14 | — | — | US | disclosed |
| US-12296043-B2 | Liquisoft capsules | PATHEON SOFTGELS INC. (US) | 2025-05-13 | — | — | US | disclosed |
| CN-119925285-A | Pharmaceutical composition comprising benzoglazimine, use thereof and preparation method thereof | 阿尔法认知公司 | 2025-05-06 | — | — | CN | disclosed |
| WO-2025042756-A2 | RAPID RELEASE SOFTGEL FORMULATION | PATHEON SOFTGELS INC. (US) | 2025-02-27 | — | — | WO | disclosed |
| EP-4510999-A1 | PROCESSES FOR PREPARATION OF 3-D PRINTED PHARMACEUTICAL PRODUCTS | Bristol-Myers Squibb Company (US) | 2025-02-26 | — | — | EP | disclosed |
| WO-2023205619-A1 | PROCESSES FOR PREPARATION OF 3-D PRINTED PHARMACEUTICAL PRODUCTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2023-10-26 | — | — | WO | disclosed |
| US-20220211616-A1 | LIQUISOFT CAPSULES | PATHEON SOFTGELS INC (US) | 2022-07-07 | — | — | US | disclosed |
| US-9238821-B2 | Metabolic engineering for plant disease resistance | THE SAMUEL ROBERTS NOBLE FOUNDATION, INC. (US) | 2016-01-19 | — | — | US | disclosed |
| US-20100319084-A1 | METABOLIC ENGINEERING FOR PLANT DISEASE RESISTANCE | THE SAMUEL ROBERTS NOBLE FOUNDATION | 2010-12-16 | — | — | US | disclosed |
| US-4036694-A | ADDING A-GALACTOSIDASE, THEN QUICKLIME | HOKKAIDO SUGAR CO., LTD. (JA) | 1977-07-19 | — | — | US | disclosed |